Great Oak Capital Partners LLC Takes $264,000 Position in Johnson & Johnson $JNJ

Key Points

• Great Oak Capital Partners LLC acquired a new position in Johnson & Johnson, purchasing 1,684 shares valued at approximately $264,000 during the second quarter.
• Analyst ratings for Johnson & Johnson have improved, with several brokerages increasing their price targets and rating the stock between "Buy" and "Overweight", indicating strong market confidence.
• Johnson & Johnson reported a 5.8% year-over-year revenue increase for the last quarter, achieving $23.74 billion and exceeding analysts' expectations, while also recently declaring a quarterly dividend of $1.30 per share.

Great Oak Capital Partners LLC purchased a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,684 shares of the company's stock, valued at approximately $264,000.

Several other large investors also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC raised its position in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the first quarter worth about $48,000. von Borstel & Associates Inc. bought a new position in Johnson & Johnson during the 1st quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson during the 1st quarter valued at about $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on JNJ. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Tuesday, September 16th. UBS Group lifted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $167.00 to $206.00 in a research note on Tuesday. Finally, Wall Street Zen raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $181.40.

Johnson & Johnson Trading Up 0.6%

Shares of NYSE:JNJ opened at $177.71 on Friday. The business's 50-day moving average is $174.09 and its 200 day moving average is $161.97. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The firm has a market capitalization of $427.99 billion, a P/E ratio of 19.01, a P/E/G ratio of 2.25 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the firm earned $2.82 earnings per share. The company's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.